New drug aims to plug kidney leaks in multiple diseases

NCT ID NCT04573920

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests the drug atrasentan in 103 adults with various kidney diseases that cause protein leakage, including IgA nephropathy and FSGS. Participants take a daily tablet to see if it reduces protein in urine, a sign of kidney damage. The goal is to find a new way to slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atrasentan
What this could lead to: If successful, this could point toward a new treatment option to slow kidney damage in several proteinuric glomerular diseases.
What could go wrong: This is an early-phase, open-label study with no placebo group, so results may not be definitive. The drug may not work for all conditions tested or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alport syndrome diabetic kidney disease focal segmental glomerulosclerosis hereditary nephritis IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPORT SYNDROME DIABETIC KIDNEY DISEASE DIABETIC NEPHROPATHY TYPE 2 FOCAL SEGMENTAL GLOMERULOSCLEROSIS IGA NEPHROPATHY IMMUNOGLOBULIN A NEPHROPATHY

Contacts and locations

Locations

Academic Medical Research Institute

Los Angeles, California, 90022, United States
Baylor Scott and White

Dallas, Texas, 75246, United States
Brookview Hills Research Assoc

Winston-Salem, North Carolina, 27103, United States
Colorado Kidney Care Nephrology

Denver, Colorado, 80230, United States
DaVita Clinical Research

Las Vegas, Nevada, 89146, United States
Kidney Disease Medical Group

Glendale, California, 91206, United States
Milwaukee Nephrologists SC

Wauwatosa, Wisconsin, 53226, United States
Mountain Kidney And Hyper Associa

Asheville, North Carolina, 28801, United States
North America Research Institute

San Dimas, California, 91773, United States
Northwest Louisiana Nephrology Research

Shreveport, Louisiana, 71101-4440, United States
Novartis Investigative Site

Gosford, New South Wales, 2250, Australia
Novartis Investigative Site

Herston, Queensland, 4029, Australia
Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Reservoir, Victoria, 3073, Australia
Novartis Investigative Site

St Albans, Victoria, 3021, Australia
Novartis Investigative Site

St Leonards, 2065, Australia
Novartis Investigative Site

Roma, RM, 00165, Italy
Novartis Investigative Site

Cheonan, Chungcheongnam-do, 330-721, South Korea
Novartis Investigative Site

Anyang-si, Gyeonggi-do, 14068, South Korea
Novartis Investigative Site

Seoul, Korea, 02841, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 134 727, South Korea
Novartis Investigative Site

Port de Sagunt, Valencia, 46520, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Lugo, 27004, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Majadahonda, 28222, Spain
Novartis Investigative Site

Sheffield, South Yorkshire, S10 2JF, United Kingdom
Novartis Investigative Site

London, E1 1BB, United Kingdom
Prolato Clinical Research Center

Houston, Texas, 77054, United States
Stanford U School Of Medicine

Stanford, California, 94305, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
Uni of Minnesota Hos and Clinics

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.